JP2024113040A5 - - Google Patents

Download PDF

Info

Publication number
JP2024113040A5
JP2024113040A5 JP2024090480A JP2024090480A JP2024113040A5 JP 2024113040 A5 JP2024113040 A5 JP 2024113040A5 JP 2024090480 A JP2024090480 A JP 2024090480A JP 2024090480 A JP2024090480 A JP 2024090480A JP 2024113040 A5 JP2024113040 A5 JP 2024113040A5
Authority
JP
Japan
Prior art keywords
fragment
peptide linker
region
domain
isolated heteromultimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024090480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024113040A (ja
Filing date
Publication date
Priority claimed from JP2021570175A external-priority patent/JP7500619B2/ja
Application filed filed Critical
Publication of JP2024113040A publication Critical patent/JP2024113040A/ja
Publication of JP2024113040A5 publication Critical patent/JP2024113040A5/ja
Pending legal-status Critical Current

Links

JP2024090480A 2019-05-30 2024-06-04 抗体の二量体化を促進するためのヒンジ領域の操作 Pending JP2024113040A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962854907P 2019-05-30 2019-05-30
US62/854,907 2019-05-30
JP2021570175A JP7500619B2 (ja) 2019-05-30 2020-05-29 抗体の二量体化を促進するためのヒンジ領域の操作
PCT/US2020/035196 WO2020243477A2 (en) 2019-05-30 2020-05-29 Engineering the hinge region to drive antibody dimerization

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021570175A Division JP7500619B2 (ja) 2019-05-30 2020-05-29 抗体の二量体化を促進するためのヒンジ領域の操作

Publications (2)

Publication Number Publication Date
JP2024113040A JP2024113040A (ja) 2024-08-21
JP2024113040A5 true JP2024113040A5 (enExample) 2025-01-27

Family

ID=72234906

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021570175A Active JP7500619B2 (ja) 2019-05-30 2020-05-29 抗体の二量体化を促進するためのヒンジ領域の操作
JP2024090480A Pending JP2024113040A (ja) 2019-05-30 2024-06-04 抗体の二量体化を促進するためのヒンジ領域の操作

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021570175A Active JP7500619B2 (ja) 2019-05-30 2020-05-29 抗体の二量体化を促進するためのヒンジ領域の操作

Country Status (12)

Country Link
US (1) US20220235148A1 (enExample)
EP (1) EP3976643A2 (enExample)
JP (2) JP7500619B2 (enExample)
KR (1) KR20220016139A (enExample)
CN (2) CN114174344B (enExample)
AU (1) AU2020283890A1 (enExample)
CA (1) CA3141690A1 (enExample)
EA (1) EA202193322A1 (enExample)
MX (1) MX2021014534A (enExample)
SG (1) SG11202112926YA (enExample)
TW (2) TWI879770B (enExample)
WO (1) WO2020243477A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113416258B (zh) * 2019-10-24 2023-08-29 北京免疫方舟医药科技有限公司 一种多特异性抗体及其制备方法和用途
WO2022223016A1 (en) * 2021-04-23 2022-10-27 Chimagen Biosciences, Ltd Heterodimeric antibodies and antigen-binding fragment thereof
EP4559933A1 (en) * 2022-07-22 2025-05-28 Innovent Biologics (Suzhou) Co., Ltd. Mutant promoting homologous pairing of heavy and light chains of multispecific antibody
CN115232214A (zh) * 2022-08-16 2022-10-25 广州市拜沃思生物科技有限公司 一种双特异性抗体及其制备方法和应用
TW202506725A (zh) * 2023-04-07 2025-02-16 美商麥迪紐有限責任公司 三特異性工程化抗體
WO2024242490A1 (ko) * 2023-05-24 2024-11-28 삼성바이오로직스 주식회사 Ch3 도메인 변이체 또는 이를 포함하는 이중 특이적 항체
WO2025167974A1 (zh) * 2024-02-07 2025-08-14 上海齐鲁制药研究中心有限公司 多特异性抗体或抗原结合片段

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル,インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
AU2249592A (en) 1991-06-14 1993-01-12 Dnx Corporation Production of human hemoglobin in transgenic pigs
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
SG170750A1 (en) 2006-03-17 2011-05-30 Biogen Idec Inc Stabilized polypeptide compositions
US8280711B2 (en) 2007-03-12 2012-10-02 ESBATech, an Alcon Biomedical Research Unit, LLC. Sequence based engineering and optimization of single chain antibodies
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
WO2009000099A2 (en) 2007-06-25 2008-12-31 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
CN102369215B (zh) 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
WO2011143545A1 (en) * 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
CN109517059B (zh) * 2011-06-30 2023-03-28 中外制药株式会社 异源二聚化多肽
DK2771364T3 (da) 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
CA3111357A1 (en) * 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
BR112015029788B1 (pt) * 2013-05-31 2024-01-02 Zymeworks Inc HETERO-MULTÍMERO, USO E MÉTODO PARA PREPARAR DO MESMO, COMPOSIÇÃO FARMACÊUTICA E MÉTODO PARA REDUZIR FUNÇÃO EFETORA DE UM CONSTRUTO IgG FC
CN105980400B (zh) 2013-07-31 2021-05-07 美国安进公司 生长分化因子15(gdf-15)构建体
ES2936810T3 (es) 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
WO2018030806A1 (ko) 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물

Similar Documents

Publication Publication Date Title
JP2024113040A5 (enExample)
JP2020114210A5 (enExample)
JP2020180158A5 (enExample)
JP2013515508A5 (enExample)
JP2021503455A5 (enExample)
CN115057936A (zh) 异源二聚体多特异性抗体形式
IL276903B1 (en) Bispecific egfr/cd16 antigen-binding protein
JPWO2019129221A5 (enExample)
JP2022009816A5 (enExample)
JP2020505919A5 (enExample)
JPWO2019204564A5 (enExample)
US20180371088A1 (en) TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY
JPWO2022094299A5 (enExample)
JPWO2019175368A5 (enExample)
JPWO2020037150A5 (enExample)
JPWO2022042488A5 (enExample)
JP2024502095A (ja) 二重または多重特異性抗体{Bi or Multi-Specific Antibody}
JPWO2021170068A5 (enExample)
JPWO2020073131A5 (enExample)
JPWO2023056252A5 (enExample)
JPWO2020102555A5 (enExample)
JPWO2020053446A5 (enExample)
JPWO2021119531A5 (enExample)
JPWO2021052349A5 (enExample)
JPWO2021207072A5 (enExample)